Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Bhuvanesh Dave Ph.D.

Bhuvanesh Dave, Ph.D

Bhuvanesh Dave, Ph.D.

Bhuvanesh Dave, Ph.D.

Assistant Member 
Cancer Research Program
The Methodist Hospital Research Institute

E-mail: bdave@houstonmethodist.org
Phone: 713-441-7392


B.Sc.   CCS University, Meerut, India (Zoology, Botany and Chemistry)
M. Res.   GND University Amritsar, India (Biotechnology)
Ph.D.   University of Arkansas for Medical Sciences, Little Rock, AR (Biochemistry & Molecular Biology)

Postdoctoral Training

Postdoctoral Fellow, Arkansas Children's Hospital, Little Rock, AR (Breast Cancer Prevention)

Postdoctoral Fellow, MD Anderson Cancer Center, Houston, TX (Cancer)

Postdoctoral Fellow, Baylor College of Medicine, Houston, TX (Breast Cancer)



Dr. Bhuvanesh Dave earned his Ph.D. in Biochemistry and Molecular Biology from the University of Arkansas for Medical Sciences, Little Rock, AR, in 2005. He received postdoctoral training in the Arkansas Children’s hospital where he worked on the role of soy and whey proteins in the prevention of breast cancer, focusing on the role of PTEN in the mechanism of prevention. He continued his training with mouse models of cancer at the MD Anderson Cancer Center and completed his training at the Baylor College of Medicine, identifying key molecular targets for breast cancer treatment.  Dr. Bhuvanesh Dave is an Assistant Member of The Methodist Hospital Research Institute Cancer Research Program, and directs a research focusing on the role of autophagy in breast and pancreatic cancer survivorship. His additional area of interest is siRNA targeting of  breast cancer tumor initiating cells. Dr. Dave has served as an editor of the International Journal of Breast Cancer since 2010 and is an invited reviewer for multiple journals.

Description of Research

Dr. Dave's research focuses on targeting self-renewal pathways of tumor initiating cells in pancreatic and breast cancer. His lab studies the biology of tumor initiating cells and is developing new cancer therapies based on the understanding of tumor initiating cells using human cancer in mouse models as preclinical models. Current studies focus on the roles of autophagy and hypoxia in the survival of tumor initiating cells.

Major Areas of Research

Cancer, stem cells, tumor initiation, autophagy, high throughput

Recent Publications

Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012 Jan 19;14(1):202. PMID: 22264257.

Dave B, Landis MD, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT, Tweardy DJ, Chang JC. Selective small molecule stat3 inhibitor reduces breast cancer tumor-initiating
cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012;7(8):e30207. Epub 2012 Aug 6. PMID: 22879872.

Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6. Epub 2011 Mar 8. PMID: 21385943.

Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, Gonzalez-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC et al: Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30(40):4163-4174. PMID: 21499296.

Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E et al: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011, 108(12):5021-5026. PMID: 21385943. 

Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC. A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat. 2012 Apr;132(3):993-1000. Epub 2011 Jul 13. PMID: 21750966.

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J et al: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011, 29(2):166-173.

Dave B, Wynne R, Su Y, Korourian S, Chang JC, Simmen RC: Enhanced mammary progesterone receptor-A isoform activity in the promotion of mammary tumor progression by dietary soy in rats. Nutr Cancer 2010, 62(6):774-782.

Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE et al: DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010, 123(1):189-196.

Crabtree JS, Jelinsky SA, Harris HA, Choe SE, Cotreau MM, Kimberland ML, Wilson E, Saraf KA, Liu W, McCampbell AS et al: Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 2009, 69(15):6171-6178.

Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL: PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 2009, 174(5):1869-1879.

Dave B, Chang J: Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia 2009, 14(1):79-82.

Jennings TA, Mackintosh SG, Harrison MK, Sikora D, Sikora B, Dave B, Tackett AJ, Cameron CE, Raney KD: NS3 helicase from the hepatitis C virus can function as a monomer or oligomer depending on enzyme and substrate concentrations. J Biol Chem 2009, 284(8):4806-4814.

Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL: Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 2008, 14(9):2543-2550.